A case of vascularized corneal opacity treated with aflibercept

Background: Corneal neovascularization (CNV) is a serious condition that can lead to a profound decline in vision. Current research on treating CNV with angiogenesis inhibitors is underway in numerous centers, and a number of studies have demonstrated the efficacy of this approach. Purpose: To prese...

Full description

Saved in:
Bibliographic Details
Published in:Oftalmologicheskiĭ zhurnal. 2020-02, Vol.84 (1), p.54-56
Main Authors: Cholak, A., Nasinnyk, I., Kostenko, P., Iakimenko, S., Korol, A.
Format: Article
Language:English
Subjects:
aflibercept
angiogenesis inhibitor
corneal neovascularization
fluorescein angiography
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Corneal neovascularization (CNV) is a serious condition that can lead to a profound decline in vision. Current research on treating CNV with angiogenesis inhibitors is underway in numerous centers, and a number of studies have demonstrated the efficacy of this approach. Purpose: To present a case of corneal neovascularization treated with aflibercept. Material and Methods: An ocular examination included visual acuity assessment, biomicroscopy, anterior eye photography and fluorescein angiography (FA). In addition, an area of CNV was assessed before and 6 months after a single subconjunctival injection of 4 mg (0.1ml) aflibercept. Results: An area of CNV decreased from 38,081 pixels before injection to 20,782 at 6 months, with a reduction in 17,299 pixels. Conclusion: In the case reported here, a single subconjunctival injection of 4 mg (0.1ml) aflibercept was found to be effective for reducing corneal neovascularization at 6 weeks.
ISSN:0030-0675
2412-8740
DOI:10.31288/oftalmolzh202015456